ECSP11011552A - Administracion continua de cilengitida en tratamientos contra el cancer - Google Patents
Administracion continua de cilengitida en tratamientos contra el cancerInfo
- Publication number
- ECSP11011552A ECSP11011552A EC2011011552A ECSP11011552A ECSP11011552A EC SP11011552 A ECSP11011552 A EC SP11011552A EC 2011011552 A EC2011011552 A EC 2011011552A EC SP11011552 A ECSP11011552 A EC SP11011552A EC SP11011552 A ECSP11011552 A EC SP11011552A
- Authority
- EC
- Ecuador
- Prior art keywords
- continuous administration
- cilengitide
- against cancer
- treatments against
- ligands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La invención se relaciona con una terapia de combinación para el tratamiento de tumores y metástasis tumorales que comprende la administración continua de ligandos de integrina, preferiblemente antagonistas de integrina junto con un agente coterapéutico o formas de terapia que tengan eficacia sinergística cuando se administren de manera consecutiva con los ligandos, tales como agentes quimioterapéuticos y/o radioterapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09006941 | 2009-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011552A true ECSP11011552A (es) | 2012-01-31 |
Family
ID=43223150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011552A ECSP11011552A (es) | 2009-05-25 | 2011-12-23 | Administracion continua de cilengitida en tratamientos contra el cancer |
Country Status (16)
Country | Link |
---|---|
US (1) | US20120130146A1 (es) |
EP (1) | EP2445534A2 (es) |
JP (1) | JP2012528079A (es) |
KR (1) | KR20120104491A (es) |
CN (1) | CN102448497A (es) |
AU (1) | AU2010252280A1 (es) |
BR (1) | BRPI1011206A2 (es) |
CA (1) | CA2763275A1 (es) |
CL (1) | CL2011002962A1 (es) |
EA (1) | EA201101651A1 (es) |
EC (1) | ECSP11011552A (es) |
IL (1) | IL216537A0 (es) |
MX (1) | MX2011012491A (es) |
NZ (1) | NZ597339A (es) |
SG (1) | SG176103A1 (es) |
WO (1) | WO2010136168A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103153328A (zh) * | 2010-07-16 | 2013-06-12 | 默克专利股份有限公司 | 肽在乳腺癌和/或骨转移灶的治疗中的用途 |
EP2729180B1 (en) | 2011-07-08 | 2019-01-23 | The University of North Carolina At Chapel Hill | Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders |
JP6426001B2 (ja) | 2011-11-17 | 2018-11-21 | グリア エスピー ゼット.オー.オー. | 神経膠腫を治療するための組成物および方法 |
KR101470700B1 (ko) * | 2011-11-25 | 2014-12-12 | 서울대학교산학협력단 | 표적 항암제의 내성 극복 방법 |
US10092589B2 (en) | 2014-04-04 | 2018-10-09 | Taiho Pharmaceutical Company Limited | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer |
WO2016061256A1 (en) * | 2014-10-14 | 2016-04-21 | The University Of Chicago | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof |
US10806694B2 (en) | 2014-10-14 | 2020-10-20 | The University Of Chicago | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof |
WO2017201528A1 (en) | 2016-05-20 | 2017-11-23 | The University Of Chicago | Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof |
JP7232204B2 (ja) * | 2017-06-29 | 2023-03-02 | インサイテック・リミテッド | マイクロバブル強化超音波処置における超音波周波数およびマイクロバブルサイズの最適化 |
EP3638367A4 (en) | 2017-08-02 | 2021-07-21 | The University of Chicago | NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US5260291A (en) | 1981-08-24 | 1993-11-09 | Cancer Research Campaign Technology Limited | Tetrazine derivatives |
US4578079A (en) | 1982-08-04 | 1986-03-25 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4614517A (en) | 1982-08-04 | 1986-09-30 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4589881A (en) | 1982-08-04 | 1986-05-20 | La Jolla Cancer Research Foundation | Polypeptide |
US4661111A (en) | 1982-08-04 | 1987-04-28 | La Jolla Cancer Research Foundation | Polypeptide |
US4792525A (en) | 1982-08-04 | 1988-12-20 | La Jolla Cancer Research Foundation | Tetrapeptide |
US4517686A (en) | 1982-08-04 | 1985-05-21 | La Jolla Cancer Research Foundation | Polypeptide |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
WO1991003493A1 (en) | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
EP0553244B8 (en) | 1990-10-05 | 2005-06-08 | Celldex Therapeutics, Inc. | Targeted immunostimulation with bispecific reagents |
EP0563214A4 (en) | 1990-12-04 | 1994-08-17 | Wistar Inst | Bifunctional antibodies and method of preparing same |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
US5407804A (en) | 1992-05-22 | 1995-04-18 | Applied Genetics Inc. | Assays for O6 -methylguanine-DNA methyltransferase |
GB9224888D0 (en) | 1992-11-27 | 1993-01-13 | Univ Singapore | Monoclonal antibody |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
AU701776B2 (en) | 1994-05-27 | 1999-02-04 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
NZ290008A (en) | 1994-06-29 | 1998-08-26 | Smithkline Beecham Corp | Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle |
IT1271688B (it) | 1994-08-04 | 1997-06-04 | Menarini Ricerche Sud Spa | Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche |
JPH10504825A (ja) | 1994-08-22 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | 二環式化合物 |
WO1996026190A1 (en) | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
EP0910563B1 (en) | 1995-06-29 | 2003-05-02 | Smithkline Beecham Corporation | Integrin receptor antagonists |
DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
EP0906103A1 (en) | 1995-12-29 | 1999-04-07 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
TR199801253T2 (xx) | 1995-12-29 | 1998-12-21 | Smithkline Beecham Corporation | Vitronektin resept�r� antagonistleri. |
JP2000502708A (ja) | 1995-12-29 | 2000-03-07 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
DE69707843T2 (de) | 1996-03-20 | 2002-05-16 | Aventis Pharma Sa | TRIZYCLISCHE VERBINDUNGEN MIT WIRKUNG AUF INTEGRINE, BESONDERS AUF DAS ALPHAvBETA3-INTEGRIN, VERFAHREN ZUR IHRER HERSTELLUNG UND ZWISCHENPRODUKTE DES VERFAHRENS, IHRE VERWENDUNG ALS ARZNEIMITTEL UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN |
JP2000508319A (ja) | 1996-04-10 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | αvβ3拮抗薬 |
US5925655A (en) | 1996-04-10 | 1999-07-20 | Merck & Co., Inc. | αv β3 antagonists |
WO1997041844A1 (en) | 1996-05-09 | 1997-11-13 | Alcon Laboratories, Inc. | Combinations of angiostatic compounds |
JP2002515036A (ja) | 1996-05-31 | 2002-05-21 | ザ スクリップス リサーチ インスティテュート | α▲下V▼β▲下5▼媒介血管形成の抑制に有用な方法および組成物 |
US6017704A (en) | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
CA2263999A1 (en) | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
US5981546A (en) | 1996-08-29 | 1999-11-09 | Merck & Co., Inc. | Integrin antagonists |
EP0946180A4 (en) | 1996-10-07 | 2003-07-23 | Smithkline Beecham Corp | METHODS FOR STIMULATING BONE FORMATION |
WO1998018461A1 (en) | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
US5919792A (en) | 1996-10-30 | 1999-07-06 | Merck & Co., Inc. | Integrin antagonists |
CA2268940A1 (en) | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
JP2001506632A (ja) | 1996-12-09 | 2001-05-22 | イーライ リリー アンド カンパニー | インテグリン拮抗物質 |
DE19653646A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
CO4920232A1 (es) | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin |
JP2001509176A (ja) | 1997-01-17 | 2001-07-10 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
AU751659B2 (en) | 1997-05-02 | 2002-08-22 | Genentech Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
EP1000031A4 (en) | 1997-07-25 | 2001-08-16 | Smithkline Beecham Corp | VITRONECTIN RECEPTOR ANTAGONISTS |
JP2001511452A (ja) | 1997-08-04 | 2001-08-14 | スミスクライン・ビーチャム・コーポレイション | インテグリン受容体アンタゴニスト |
EP1027337A4 (en) | 1997-09-04 | 2002-04-03 | Smithkline Beecham Corp | Integrin receptor Antagonist |
AR015446A1 (es) | 1997-09-19 | 2001-05-02 | Smithkline Beecham Corp | Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios |
FR2768736B1 (fr) | 1997-09-24 | 2000-05-26 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
KR20010024249A (ko) | 1997-09-24 | 2001-03-26 | 스튜어트 알. 수터 | 비트로넥틴 수용체 길항제 |
FR2768734B1 (fr) | 1997-09-24 | 2000-01-28 | Roussel Uclaf | Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant |
AU9577498A (en) | 1997-09-24 | 1999-04-12 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
US6017926A (en) | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
WO1999031061A1 (en) | 1997-12-17 | 1999-06-24 | Merck & Co., Inc. | Integrin receptor antagonists |
ES2243015T3 (es) | 1997-12-17 | 2005-11-16 | MERCK & CO., INC. | Antagonistas del receptor de integrina. |
CA2315189C (en) | 1997-12-17 | 2005-04-19 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
EP1049718B1 (en) | 1998-01-23 | 2006-04-05 | MERCK PATENT GmbH | Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin |
CA2338275A1 (en) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
AU748621B2 (en) | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
DE69930764D1 (de) | 1998-12-23 | 2006-05-18 | G D Searle Llc St Louis | Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia |
SK17442001A3 (sk) | 1999-06-02 | 2002-03-05 | Merck & Co., Inc. | Deriváty kyseliny nonánovej, farmaceutický prostriedok s ich obsahom a ich použitie |
EP1328656A4 (en) | 2000-09-29 | 2005-09-14 | Univ Johns Hopkins Med | METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY WITH ALKYLATING AGENTS |
CN101370522A (zh) * | 2006-01-18 | 2009-02-18 | 默克专利有限公司 | 使用整联蛋白配体治疗癌症的特别疗法 |
EP2101805B1 (en) * | 2007-01-18 | 2012-11-07 | Merck Patent GmbH | Integrin ligands for use in treating cancer |
-
2010
- 2010-05-25 CA CA2763275A patent/CA2763275A1/en not_active Abandoned
- 2010-05-25 WO PCT/EP2010/003162 patent/WO2010136168A2/en active Application Filing
- 2010-05-25 KR KR1020117030945A patent/KR20120104491A/ko not_active Application Discontinuation
- 2010-05-25 AU AU2010252280A patent/AU2010252280A1/en not_active Abandoned
- 2010-05-25 SG SG2011084381A patent/SG176103A1/en unknown
- 2010-05-25 MX MX2011012491A patent/MX2011012491A/es not_active Application Discontinuation
- 2010-05-25 US US13/322,391 patent/US20120130146A1/en not_active Abandoned
- 2010-05-25 EP EP20100721342 patent/EP2445534A2/en not_active Withdrawn
- 2010-05-25 EA EA201101651A patent/EA201101651A1/xx unknown
- 2010-05-25 BR BRPI1011206A patent/BRPI1011206A2/pt not_active Application Discontinuation
- 2010-05-25 JP JP2012511202A patent/JP2012528079A/ja active Pending
- 2010-05-25 CN CN2010800227000A patent/CN102448497A/zh active Pending
- 2010-05-25 NZ NZ597339A patent/NZ597339A/xx not_active IP Right Cessation
-
2011
- 2011-11-22 IL IL216537A patent/IL216537A0/en unknown
- 2011-11-24 CL CL2011002962A patent/CL2011002962A1/es unknown
- 2011-12-23 EC EC2011011552A patent/ECSP11011552A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP2445534A2 (en) | 2012-05-02 |
IL216537A0 (en) | 2012-02-29 |
WO2010136168A3 (en) | 2011-07-07 |
WO2010136168A2 (en) | 2010-12-02 |
AU2010252280A1 (en) | 2012-01-19 |
CL2011002962A1 (es) | 2012-06-01 |
NZ597339A (en) | 2013-10-25 |
SG176103A1 (en) | 2011-12-29 |
JP2012528079A (ja) | 2012-11-12 |
US20120130146A1 (en) | 2012-05-24 |
KR20120104491A (ko) | 2012-09-21 |
EA201101651A1 (ru) | 2012-08-30 |
MX2011012491A (es) | 2011-12-14 |
BRPI1011206A2 (pt) | 2016-03-15 |
WO2010136168A8 (en) | 2011-09-22 |
CA2763275A1 (en) | 2010-12-02 |
CN102448497A (zh) | 2012-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011552A (es) | Administracion continua de cilengitida en tratamientos contra el cancer | |
WO2007084670A3 (en) | Specific therapy using integrin ligands for treating cancer | |
CO2017007662A2 (es) | Terapias de combinación para el tratamiento de cánceres | |
ECSP109969A (es) | Terapia especifica y medicamento que usan ligando de integrina para tratar cancer | |
MA40437A (fr) | Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux | |
WO2014145642A3 (en) | Nrf2 small molecule inhibitors for cancer therapy | |
CO6670568A2 (es) | Métodos de terapia combinada para tratar enfermedades profilerativas | |
NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
NZ719049A (en) | Cancer treatment with combination of plinabulin and taxane | |
MX2018007933A (es) | Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina. | |
NI201500100A (es) | Mãtodos de tratamiento de la deficiencia de hierro con pirofosfato fãrrico soluble | |
MX2020001727A (es) | Terapia de combinacion. | |
MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
WO2015038896A3 (en) | Wilforlide a for overcoming chemotherapy resistance | |
MX2015007280A (es) | Terapia de combinacion para cancer. | |
MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
WO2007082742A8 (en) | Isolated organ perfusion combination therapy of cancer | |
WO2010057596A3 (en) | New therapy and medicament using integrin ligands for treating cancer | |
MX2021001081A (es) | Terapia de combinacion para el tratamiento del cancer. | |
MX2019014842A (es) | Uso de una combinación de ivosidenib y radiación para tratar gliomas. |